Relmada Therapeutics entered into a $160 million private placement for 29.5M common shares at $4.75 and pre-funded warrants for 4.2M shares at $4.749, closing March 11, 2026, with proceeds for working capital and R&D including NDV-01. Concurrently announced positive 12-month Phase 2 interim data for NDV-01 in high-risk NMIBC showing 76% CR rate overall and 80% in BCG-unresponsive patients.
Key takeaways
Private placement: 29,474,569 common shares at $4.75/share; pre-funded warrants for 4,210,527 shares at $4.749/warrant; aggregate $160M
Closing expected March 11, 2026, subject to customary conditions